e-Therapeutics is a pioneer in the field of network-driven drug discovery, NDD, using big data advanced network analytics and machine learning to identify compounds capable of significantly disrupting disease relevant biological networks. Just as big pharma is looking at in silico solutions to address the ongoing R&D productivity issues, e-Therapeutics is demonstrating the utility of its platform in areas of current interest. This fuels our confidence that the company will sign one or more drug discovery alliances in the coming year. To be conservative, our DCF valuation is unchanged at £53.8m or 20.4p/share.
04 Jan 2018
Good progress as first commercial deal sought
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Good progress as first commercial deal sought
e-Therapeutics plc (ETX:LON) | 9.3 0 0.3% | Mkt Cap: 54.3m
- Published:
04 Jan 2018 -
Author:
Mick Cooper PhD -
Pages:
12
e-Therapeutics is a pioneer in the field of network-driven drug discovery, NDD, using big data advanced network analytics and machine learning to identify compounds capable of significantly disrupting disease relevant biological networks. Just as big pharma is looking at in silico solutions to address the ongoing R&D productivity issues, e-Therapeutics is demonstrating the utility of its platform in areas of current interest. This fuels our confidence that the company will sign one or more drug discovery alliances in the coming year. To be conservative, our DCF valuation is unchanged at £53.8m or 20.4p/share.